CL2019000045A1 - Derivados etinilo. - Google Patents

Derivados etinilo.

Info

Publication number
CL2019000045A1
CL2019000045A1 CL2019000045A CL2019000045A CL2019000045A1 CL 2019000045 A1 CL2019000045 A1 CL 2019000045A1 CL 2019000045 A CL2019000045 A CL 2019000045A CL 2019000045 A CL2019000045 A CL 2019000045A CL 2019000045 A1 CL2019000045 A1 CL 2019000045A1
Authority
CL
Chile
Prior art keywords
compounds
ethynyl derivatives
isometer
emesis
neuroprotection
Prior art date
Application number
CL2019000045A
Other languages
English (en)
Inventor
Georg Jaeschke
Antonio Ricci
Barbara Biemans
Fionn O`Hara
Daniel Rueher
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2019000045A1 publication Critical patent/CL2019000045A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE FÓRMULAS IA Y IB, O A UNA SAL O SAL DE ADICIÓN DE ÁCIDO FARMACÉUTICAMENTE ACEPTABLE, A UNA MEZCLA RACÉMICA O A SU ENANTIÓMERO Y/O ISÓMERO ÓPTICO Y/O ESTEREOISÓMERO CORRESPONDIENTE DE LOS MISMOS. LOS COMPUESTOS PUEDEN UTILIZARSE EN EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON, LA ANSIEDAD, LA EMESIS, EL TRASTORNO OBSESIVO-COMPULSIVO, EL AUTISMO, LA NEUROPROTECCIÓN, EL CÁNCER, LA DEPRESIÓN Y LA DIABETES DE TIPO 2.
CL2019000045A 2016-07-18 2019-01-07 Derivados etinilo. CL2019000045A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16179837 2016-07-18

Publications (1)

Publication Number Publication Date
CL2019000045A1 true CL2019000045A1 (es) 2019-06-07

Family

ID=56418435

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000045A CL2019000045A1 (es) 2016-07-18 2019-01-07 Derivados etinilo.

Country Status (31)

Country Link
US (3) US20190144458A1 (es)
EP (1) EP3484889B1 (es)
JP (1) JP6936305B2 (es)
KR (1) KR20190026805A (es)
CN (1) CN109476671B (es)
AR (1) AR109075A1 (es)
AU (1) AU2017299083B2 (es)
BR (1) BR112019000314A2 (es)
CA (1) CA3030788A1 (es)
CL (1) CL2019000045A1 (es)
CO (1) CO2018013824A2 (es)
CR (1) CR20190014A (es)
DK (1) DK3484889T3 (es)
ES (1) ES2826389T3 (es)
HR (1) HRP20201615T1 (es)
HU (1) HUE051006T2 (es)
IL (1) IL263884A (es)
LT (1) LT3484889T (es)
MA (1) MA45665B1 (es)
MX (1) MX2019000442A (es)
PE (1) PE20190382A1 (es)
PH (1) PH12019500119A1 (es)
PL (1) PL3484889T3 (es)
PT (1) PT3484889T (es)
RS (1) RS60908B1 (es)
RU (1) RU2745068C2 (es)
SG (1) SG11201811829QA (es)
SI (1) SI3484889T1 (es)
TW (1) TWI729169B (es)
WO (1) WO2018015235A1 (es)
ZA (1) ZA201900113B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107580598B (zh) 2015-07-15 2020-11-13 豪夫迈·罗氏有限公司 作为代谢型谷氨酸受体调节剂的乙炔基衍生物
CN110183456A (zh) * 2019-07-11 2019-08-30 河南师范大学 一种2-芳基吲唑琥珀酰亚胺螺环化合物的合成方法
US11515154B2 (en) * 2020-10-27 2022-11-29 Applied Materials, Inc. Selective deposition of a passivation film

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003298889A1 (en) * 2002-12-04 2004-06-23 Merck & Co., Inc. Spirocyclic ureas, compositions containing such compounds and methods of use
UA90145C2 (ru) 2005-05-24 2010-04-12 Лаборатуар Сероно С.А. Трициклические спиро-производные как модуляторы crth2
CN101528711A (zh) 2006-08-31 2009-09-09 先灵公司 可用作抗细菌剂的乙内酰脲衍生物
WO2008151184A1 (en) 2007-06-03 2008-12-11 Vanderbilt University Benzamide mglur5 positive allosteric modulators and methods of making and using same
WO2011029104A1 (en) 2009-09-04 2011-03-10 Vanderbilt University Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8389536B2 (en) 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
US8759377B2 (en) 2009-11-23 2014-06-24 Vanderbilt University Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
US8772300B2 (en) 2011-04-19 2014-07-08 Hoffmann-La Roche Inc. Phenyl or pyridinyl-ethynyl derivatives
HUE025031T2 (en) 2011-04-26 2016-02-29 Hoffmann La Roche Ethinyl derivatives as positive allosteric modulators of MGLUR5
US10533000B2 (en) 2011-05-26 2020-01-14 Sunovion Pharmaceuticals, Inc. Metabotrophic glutamate receptor 5 modulators and methods of use thereof
JP6205354B2 (ja) * 2011-07-06 2017-09-27 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のための化合物
US20130123254A1 (en) 2011-09-30 2013-05-16 Barbara Biemans Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification
UA110862C2 (uk) 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5
NZ703537A (en) 2012-10-18 2018-06-29 Hoffmann La Roche Ethynyl derivatives
SG11201501375YA (en) 2012-10-18 2015-03-30 Hoffmann La Roche Ethynyl derivatives as modulators of mglur5 receptor activity
CN105121424B (zh) 2013-02-18 2019-01-22 华领医药技术（上海）有限公司 mGluR调节剂
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
DK3049409T3 (en) * 2013-09-25 2017-07-10 Hoffmann La Roche ethynyl derivatives
TWI649310B (zh) 2014-01-10 2019-02-01 赫孚孟拉羅股份公司 乙炔基衍生物
AU2015222303B2 (en) 2014-02-25 2019-02-28 F. Hoffmann-La Roche Ag Ethynyl derivatives
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
WO2016146600A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag 3-(4-ethynylphenyl)hexahydropyrimidin-2,4-dione derivatives as modulators of mglur4
CN107580598B (zh) * 2015-07-15 2020-11-13 豪夫迈·罗氏有限公司 作为代谢型谷氨酸受体调节剂的乙炔基衍生物
US10391998B2 (en) 2016-11-16 2019-08-27 Ford Global Technologies, Llc Vehicle systems and methods for reducing electrified vehicle noise, vibration, and harshness

Also Published As

Publication number Publication date
US20190144458A1 (en) 2019-05-16
PE20190382A1 (es) 2019-03-08
PT3484889T (pt) 2020-10-15
AR109075A1 (es) 2018-10-24
MX2019000442A (es) 2019-06-20
DK3484889T3 (da) 2020-10-26
SG11201811829QA (en) 2019-02-27
PH12019500119A1 (en) 2019-12-11
IL263884A (en) 2019-01-31
AU2017299083B2 (en) 2021-06-24
RS60908B1 (sr) 2020-11-30
CN109476671A (zh) 2019-03-15
US20220127275A1 (en) 2022-04-28
EP3484889B1 (en) 2020-08-19
US20200255440A1 (en) 2020-08-13
US11242349B2 (en) 2022-02-08
CO2018013824A2 (es) 2018-12-28
JP2019521158A (ja) 2019-07-25
PL3484889T3 (pl) 2020-12-28
CR20190014A (es) 2019-03-04
MA45665B1 (fr) 2020-11-30
TW201805287A (zh) 2018-02-16
WO2018015235A1 (en) 2018-01-25
CN109476671B (zh) 2021-09-24
CA3030788A1 (en) 2018-01-25
TWI729169B (zh) 2021-06-01
RU2019102757A3 (es) 2020-08-18
RU2745068C2 (ru) 2021-03-18
AU2017299083A1 (en) 2019-01-24
EP3484889A1 (en) 2019-05-22
HUE051006T2 (hu) 2021-01-28
ES2826389T3 (es) 2021-05-18
JP6936305B2 (ja) 2021-09-15
RU2019102757A (ru) 2020-08-18
KR20190026805A (ko) 2019-03-13
HRP20201615T1 (hr) 2020-12-11
BR112019000314A2 (pt) 2019-04-16
SI3484889T1 (sl) 2020-11-30
LT3484889T (lt) 2020-11-10
ZA201900113B (en) 2019-09-25

Similar Documents

Publication Publication Date Title
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
CL2018000036A1 (es) Derivados etinilo
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
BR112017010354A2 (pt) compostos de triazolopirimidina e usos dos mesmos
CL2019001066A1 (es) Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854)
EA201592082A1 (ru) 3,4-дигидроизохинолин-2(1h)-ильные соединения
CL2019000045A1 (es) Derivados etinilo.
PH12016501863A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
AR099047A1 (es) Derivados etinilo
CL2013002424A1 (es) Compuestos derivados de (piridin-4-il)-bencilamidas como moduladores alostericos de nachr alfa-7; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades como alzheimer, ansiedad, esquizofrenia, parkinson, entre otras.
PH12016501993A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
CL2016002064A1 (es) Derivados de etinilo.
AR104863A1 (es) Derivados imidazol
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
AR103952A1 (es) Derivados de pirimidina-diona
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
EA201792502A1 (ru) Кабазитаксел и его применение для лечения рака
IN2013MU03838A (es)
MD20150017A2 (ro) Utilizarea preparatului Polibiolin la pacienţii cu ciroză hepatică
CN302103642S (zh) 柜子
CN302120534S (zh) 瓶
CN302239733S (zh) 输液瓶（50ml5%葡萄糖注射液）
CN302270266S (zh) 成型坩埚支架